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Abstract
Targeting Nrf2 signaling appears to be an attractive approach for the treatment of maladaptive cardiac remodeling and
dysfunction; however, pharmacological modulation of the Nrf2 pathway in the cardiovascular system remains to be
established. Herein, we report that a novel synthetic triterpenoid derivative, dihydro-CDDO-trifluoroethyl amide (dh404),
activates Nrf2 and suppresses oxidative stress in cardiomyocytes. Dh404 interrupted the Keap1-Cul3-Rbx1 E3 ligase
complex-mediated Nrf2 ubiquitination and subsequent degradation saturating the binding capacity of Keap1 to Nrf2,
thereby rendering more Nrf2 to be translocated into the nuclei to activate Nrf2-driven gene transcription. A mutant Keap1
protein containing a single cysteine-to-serine substitution at residue 151 within the BTB domain of Keap1 was resistant to
dh404-induced stabilization of Nrf2 protein. In addition, dh404 did not dissociate the interaction of Nrf2 with the Keap1-
Cul3-Rbx1 E3 ligase complex. Thus, it is likely that dh404 inhibits the ability of Keap1-Cul3-Rbx1 E3 ligase complex to target
Nrf2 for ubiquitination and degradation via modifying Cys-151 of Keap1 to change the conformation of the complex.
Moreover, dh404 was able to stabilize Nrf2 protein, to enhance Nrf2 nuclear translocation, to activate Nrf2-driven
transcription, and to suppress angiotensin II (Ang II)-induced oxidative stress in cardiomyocytes. Knockdown of Nrf2 almost
blocked the anti-oxidative effect of dh404. Dh404 activated Nrf2 signaling in the heart. Taken together, dh404 appears to be
a novel Nrf2 activator with a therapeutic potential for cardiac diseases via suppressing oxidative stress.
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Introduction
Triterpenoids, synthesized in many plants, including a large
variety of vegetarian foods and medicinal herbs, are widely used as
traditional medicine of in Asian countries [1]. More than 20,000
triterpenoids exist in nature [2]. In fact, triterpenoids of oleanolic
acid (OA) and ursolic acid (UA) have emerged to be attractive
drug scaffolds because they are relatively non-toxic, cytoprotective,
hypoglycemic, anti-inflammatory, anti-hyperlipidemic, and anti-
tumorigenic [1]. To improve the pharmacological potency, novel
derivatives of OA, such as 2-cyano-3,12-dioxooleana-1,9(11)-dien-
28-oic acid (CDDO), CDDO methyl ester (CDDO-Me), CDDO
imidazolides (CDDO-Im), and CDDO amides (methyl amide,
CDDO-MA; ethyl amide, CDDO-EA), have been synthesized [3].
These synthetic derivatives of OA are potent multifunctional
molecules in vitro. Depending on the dose, they can suppress
inflammation, activate cytoprotective pathways, induce differenti-
ation, inhibit proliferation and induce apoptosis. In fact, they are
the most potent anti-inflammatory and anti-carcinogenic triterpe-
noinds identified [4]. Importantly, CDDO-Me that has been
tested in clinical oncology trails is currently in a phase IIb clinical
trial for the treatment of chronic kidney diseases. However, the
therapeutic potential of synthetic oleanane triterpenoids (SO) in
cardiovascular diseases has not been explored.
Molecular mechanisms underlying the pleiotropic nature of
SO are only partly understood. However; it has been recently
demonstrated that activation of nuclear factor-erythroid (NF-E)
2–related factor 2 (Nrf2) signaling is critical for the SO-mediated
anti-inflammatory and anti-carcinogenic activities [4].
Nrf2 is a member of the Cap ‘n’ Collar (CNC) family of basic
leucine zipper (bZip) transcription factors that includes NF-E2,
Nrf1-3 and Bach1-2 [5–9]. As other members of the CNC family
of bZip transcription factors, Nrf2 forms a heterodimer with its
obligatory partner Maf, thereby binding to a cis-acting enhancer
sequence known as the antioxidant response element (ARE), also
referred to as the electrophile response element (EpRE) with a core
nucleotide sequence of 59-RTGACNNNGC-39, to regulate the
basal and inducible expression of more than 200 genes that can be
grouped into several categories including antioxidant genes, phase
II detoxifying enzymes, transporters, scavenger receptor, chaper-
one proteins, transcription factors [10–12]. The protein stability
and transcriptional activity of Nrf2 is principally regulated by a
BTB-Kelch protein, Keap1 that functions as a substrate adaptor
for a cullin (Cul)3-dependent E3 ubiquitin ligase complex [10–12].
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8391Keap1 targets Nrf2 for ubiquitination and subsequent degradation
by the 26S proteasome. Mounting evidence has revealed that
Nrf2 is a major regulator of cellular defenses against various
pathological stresses in different organs including lung, liver,
gastrointestinal tract, bladder, kidney, brain, skin, and ovary. Nrf2
also appears to be an attractive drug target for the treatment or
prevention of several human disorders such as pulmonary fibrosis,
hepatic and gastrointestinal disease, carcinogenesis and neurode-
generative disease [12–23]. Of note, we have recently demon-
strated that Nrf2 is a critical negative regulator of pathological
cardiac hypertrophy and heart failure via its ability to orchestrate a
group of antioxidant genes [24]. These results suggest that
targeting Nrf2 signaling might be a novel therapeutic strategy
for the treatment of maladaptive cardiac hypertrophy and the
prevention of heart failure. Interestingly, a recent report high-
lighted the fact that the Keap1-Nrf2 system comprises discrete
sensor sites, including the Keap1 cysteines Cys-151 and Cys-275,
for a variety of Nrf2-activating compounds and special ‘‘cysteine
codes’’ are linked with the Nrf2-mediated biological actions [25].
Therefore, a novel class of synthetic SO might activate the Nrf2-
driven cardiac protective signaling via modulating ‘‘cysteine
codes’’ of Keap1-Nrf2 system.
In the present study, we report that a novel triterpenoid
derivative of dihydro-CDDO-trifluoroethyl amide (dh404) stabi-
lizes Nrf2 protein via modulating Keap1 Cys-151, thereby
activating Nrf2-driven transcriptional activity. In addition, dh404
inhibits the hypertrophic agonist angiotensin II (ANG II)-induced
formation of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) in cardiomyocytes via the activation of Nrf2
signaling. Notably, dh404 activates Nrf2 signaling in the heart.
Our results highlight a therapeutic potential of dh404 for the
treatment of heart disease.
Results
Dh404 Activates Nrf2 by Disrupting Keap1-Dependent
Suppression of Nrf2
It has been well documented that synthetic triterpenoid
derivatives are able to activate Nrf2 [4], therefore, we synthesized
a novel triterpenoid derivative of dihydro-CDDO-trifluoroethyl
amide that was named dh404 (Figure 1) and investigated the
impact of dh404 on Keap1-Nrf2 homeostasis. Firstly, we
established a system of Keap1-Nrf2 homeostasis in NIH 3T3 cells
that express negligible levels of Nrf2 and Keap1 as previously
described [26]. Briefly, different ratios of Keap1 and Nrf2
plasmids were transfected into NIH 3T3 cells. The Nrf2-driven
transcriptional activity reached the basal level when the exogenous
expression of Nrf2 and Keap1 was achieved in a ratio of 10:1
(Nrf2:Keap1) (Figure 2A). Confocal microscopic analysis clearly
indicated that HA-Nrf2 protein was efficiently sequestered in the
cytoplasm by the co-expression of CBD-Keap1 protein (Figure 2B).
Thus, we used the balanced Keap1-Nrf2 expression system in the
present study. Secondly, we determined the potential of dh404 to
activate Nrf2. As shown in Figure 2B, dh404 triggered Nrf2
nuclear translocation, suggesting that dh404 is able to activate
Nrf2. We have previously demonstrated that C273 and C288
which are distinct cysteine residues in Keap1, are required for
Keap1-mediated constitutive suppression of Nrf2 activity, and
C151, that is required for escape by Nrf2 from Keap1-dependent
suppression in response to sulforaphane and oxidative stress [26].
Accordingly, the effect of dh404 on Nrf2 transcriptional activity
was determined in the cells transfected with Nrf2, Keap1, and
these Keap1 mutants (Figure 2C). Dh404 activated Nrf2
transcriptional activity in the cells transfected with Nrf2 and
Keap1 but not with Nrf2 and C151S Keap1 mutant, suggesting
that dh404 specifically interacts with the Cys-151 residue in Keap1
leading to disruption of the Keap1-dependent suppression of Nrf2.
Dh404 Inhibits Keap1-Mediated Nrf2 Degradation by
Interfering with the Ability of Keap1-Cul3-Rbx1 E3 Ligase
Complex to Target Nrf2 for Ubiquitination
To explore the molecular mechanism by which dh404 disrupts
the Keap1-mediated suppression of Nrf2, we examined effect of
dh404 on the Keap1-mediated Nrf2 ubiquitination and subsequent
proteosome-mediated degradation as well as the assembling of
Keap1-Cul3-Rbx1 E3 ligase complex for the Nrf2 ubiquitination
and degradation in HEK293 cells as previously described [27].
We have demonstrated that Nrf2 protein turnover in cells is
very fast and most of Nrf2 proteins are rapidly degraded via the
ubiquitin-proteosome system [27]. Of interest, we observed that
dh404 treatment resulted in a decrease in the Nrf2 ubiquination
(Figure 3A). Moreover, dh404 suppressed Keap1-mediated Nrf2
degradation via a posttranscriptional modulation at the C151
residue in Keap1 (Figures 3B–D). These results indicate that
dh404 interfered with Keap1-dependent machinery for Nrf2
ubiquination and degradation via its ability to modulate Cys-151
in Keap1.
We and others have demonstrated that Keap1 functions as a
substrate adaptor protein for a Cul3/Rbx1 E3 ligase complex to
target Nrf2 ubiquitination and subsequent proteosome-mediated
degradation [27–29]. Therefore, the effect of dh404 on the
Keap1-Cul3-Rbx1complex-mediated Nrf2 degradation and the
complex assembling were determined. The input amounts of
plasmids utilized for transfections including CBD-Keap1, HA-
Cul3 andMyc-Rbx1 were carefully titrated, so that the steady-state
levels of Nrf2 protein expression were close to basal levels
(Figure 4A). Under this condition, dh404 treatment led to a
dramatic increase in Nrf2 protein levels, suggesting that dh404 is
able to inhibit the Keap1-Cul3-Rbx1 dependent Nrf2 degradation
(Figure 4B). Moreover, reciprocal immunoprecipitation and
immunobot analysis demonstrated that dh404 did not disrupt a
complex formation of Keap1-Cul3-Rbx1 in HEK293 cells
(Figure 4C).
Dh404 Increases Nrf2 Nuclear Translocation Independent
of Keap1
Several lines of evidence have revealed that a relative slow turnover
of Nrf2 in the nucleus involves Keap1-dependent and –independent
mechanisms [30–35]. Accordingly, we examined whether or not
Figure 1. Structure of dh404. A novel dihydro-CDDO-trifluoroethyl
amide (dh404) of 2-cyano-3,12-dioxooleana-1-ene-28-trifluoroethyla-
mide (C33H45F3N2O3) with a molecular weight of 574.338.
doi:10.1371/journal.pone.0008391.g001
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enhanced the association of Nrf2 and Keap1 and facilitated Nrf2
nuclear accumulation, it did not increase the nuclear levels of
Keap1 (Figure 5). These results suggest that dh404-induced Nrf2
nuclear translocation is via a mechanism independent of Keap1.
Collectively, we have demonstrated that dh404 interrupts the
Keap1-Cul3-Rbx1 E3 ligase complex-mediated Nrf2 ubiquitina-
tion and subsequent degradation thereby saturating the binding
capacity of Keap1 to Nrf2 and rendering more Nrf2 to be
translocated into nuclei to activate Nrf2-driven gene transcription.
Since dh404 does not dissociate the interaction of Nrf2 with the
Keap1-Cul3-Rbx1 E3 ligase complex, it is likely that dh404
inhibits the ability of Keap1-Cul3-Rbx1 E3 ligase complex to
target Nrf2 for ubiquitination and degradation via changing the
conformation of the complex. Moreover, Cys151 of Keap1 is the
primary sensor for dh404-mediated activation of Nrf2 signaling.
Dh404 Stabilizes Nrf2 and Activates Nrf2-Driven
Transcriptional Activity in H9C2 Cardiomyocytes
To further explore the biological relevance of dh404-induced
activation of Nrf2 signaling, we determined whether dh404
activates Nrf2 in H9C2 cardiomyocytes. As expected, dh404
stabilized Nrf2 protein, enhanced Nrf2 nuclear translocation,
leading to an increase in Nrf2-driven transcriptional activity
(Figure 6).
Dh404 Inhibits Hypertrophic Agonist-Induced Formation
of ROS and RNS in H9C2 Cardiomyocytes via the
Activating of Nrf2
To determine a functional significance of the dh404-operated
activation of Nrf2 signaling in cardiovascular system, we examined
the effect of dh404 on oxidative stress in cardiomyocytes. It has
been demonstrated in H9C2 cardiomyocytes that Ang II induces
apoptosis via NADPH oxidase activation [36]. We observed that
Ang II stimulation for 1 hour resulted in a dramatic increase in the
formation of O2N
2 and ONOON
2 in a dose-dependent manner
with a peak of O2N
2 and ONOON
2 production at concentration of
0.5 mM and 2 mM of Ang II respectively. However, Ang II did not
stimulate H2O2 formation within a detectable range (data not
shown). Adenoviral over-expression of Nrf2 inhibited both basal
and Ang II-induced O2N
2 and ONOON
2 formation in H9C2 cells,
whereas adenoviral over-expression of Nrf2 shRNA exerted
opposite effect (Figures 7A and C). The efficacy of adenoviral
over-expression of Nrf2 and Nrf2 shRNA has been established in
H9C2 cells (Figure S1). Of note, the loss of Nrf2 caused a robust
increase in the formation of ONOON
2, a key player in the
oxidative stress-mediated pathogenesis of various diseases includ-
ing cardiovascular disorders [37], suggesting a crucial role of Nrf2
in cardiovascular protection. Importantly, dh404 was not only able
to suppress the basal levels but also block the Ang II-induced
formation of O2N
2 and ONOON
2 in H9C2 cells. However, the
Figure 2. Regulation of Keap1-Nrf2 Homeostasis by dh404. A, Titration of Keap1-mediated suppression of Nrf2 transcritional activity. NIH 3T3
cells were transfected with plasmids containing an ARE-dependent firefly luciferase reporter gene (ARE-Luc), expression plasmids for wild-type HA-
Nrf2 and CBD-Keap1, and plasmids encoding Renilla luciferase to normalize transfection efficiency. The transfections were performed with 100 ng of
ARE-Luc plasmid, 10 ng of pRL-TK, 40 ng of HA-Nrf2, and 1–40 ng of CBD-Keap1, as well as different amounts of pcDNA3.1 to maintain a total level of
plasmid DNA at 200 ng. ARE reporter activity was measured 24 hours after the transfection. Results are representative of three independent
experiments. *p,0.05 vs control pcDNA3.1. B, Effect of dh404 on Nrf2 nuclear translocation. NIH 3T3 cells were transfected for 24 hours with plasmids
of HA-Nrf2 and CDB-Keap1 with a ratio of 10:1 that resulted in complete suppression of Nrf2 transcriptional activity as indicated in A. The transfected
cells were treated with dh404 (200 nM) in serum-free DMEM for 2 hours, and then subjected to immunofluorescence cofocal microscopic analysis. C,
Cysteine residues in Keap1 required for dh404-mediated Nrf2 activation. NIH 3T3 cells were transfected for 24 hours with plasmids of HA-Nrf2 and
CDB-Keap1 or plasmids of mutant Keap1 containing single cysteine-to-serine substitutions with a ratio of 10:1 as indicated. The transfected cells were
treated with or without dh404 (200 nM) in serum-free DMEM for 6 hours prior to ARE reporter assay. Results are representative of three independent
experiments. *p,0.05 vs Nrf2 transfected group.
doi:10.1371/journal.pone.0008391.g002
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absent in the cells with Nrf2 knockdown (Figures 7B and D),
demonstrating that Nrf2 is an essential mediator for dh404-
induced suppression of oxidative stress.
Dh404 Activates Nrf2 in the Heart
Finally, we explored whether dh404 activates Nrf2 in a primary
culture of cardiac myocytes and in the heart. As shown in Figure
S2, dh404 treatment led to a robust up-regulation of Nrf2 in rat
neonatal cardiomyocytes. While basal nuclear expression of Nrf2
is hardly detected, a dramatic increase in nuclear expression of
Nrf2 was observed in dh404-treated cells. A single oral
administration of dh404 significantly enhanced myocardial
expression of Nrf2 with the majority localized in cardiac myocytes
(Figure 8A). Moreover, oral dh404 administration activated
several Nrf2 downstream genes in the heart (Figure 8B), including
heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase
(NQO)-1, and thioredoxin-1 (Txn-1) that are important for
Nrf2-mediated cardiac protection [24]. These results clearly
demonstrate that dh404 activates Nrf2 in the heart, suggesting
that dh404 might exert cardioprotective effects via activating Nrf2
signaling.
Discussion
A therapeutic potential of natural triterpenoid derivatives for
cardiovascular disease has been realized for thousands of years
[1,3,38]. However, pharmaceutical approaches utilizing triterpe-
noid derivatives for the treatment of cardiovascular diseases have
yet to be established because of the complex nature of mechanisms
underlying their broad biological actions. In the present study, we
report that a novel synthetic triterpenoid derivative, dihydro-
CDDO-trifluoroethyl amide (2-cyano-3,12-dioxooleana-1-ene-28-
trifluoroethylamide) or dh404, interacts with Cys-151 of Keap1
and leads to the suppression of the Keap1/Cul3/Rbx1 complex-
mediated ubiquitination and degradation of Nrf2 proteins to
enhance Nrf2 nuclear translocation and subsequent transcriptional
events. Notably, dh404 suppresses oxidative stress via activating
Nrf2 in cardiomyocytes. A single oral administration of dh404 was
found to dramatically enhance Nrf2 activity, leading to a sustained
activation of the cardioprotective genes that are driven by Nrf2
[24]. Therefore, our results demonstrate that dh404 represents a
unique class of Nrf2 activators with a therapeutic potential for the
treatment of cardiovascular diseases.
With regards to the molecular mechanism by which dh404
activates Nrf2, several intriguing issues remain to be addressed.
Firstly, the dh404-induced Nrf2 nuclear accumulation may involve
other regulator mechanisms, such as nuclear dissociation of Nrf2
with Keap1or nuclear turnover of Nrf2 [35,39]. Secondly, dh404
might activate kinases to phosphorylate and stabilize Nrf2 as
reported for other chemical inducers [10–12]. Finally, other Cys
residues such as Cys-275 of Keap1 [25] might contribute to the
dh404-mediated activation of Nrf2.
It is noteworthy that dh404 is a unique Nrf2 activator. Unlike
dh404, we observed that oltipraz, another established Nrf2
activator, induced dramatic increases in superoxide and peroxyni-
trite generation in cardiomyocytes (Figure S3). Surprisingly, the
levels of these free radicals in cardiomyocytes treated with oltipraz
were even higher than that treated with angiotensin II, a most
important factor in the pathogenesis of hypertrophic cardiomyop-
athy [40,41]. Although it is unknown whether or not the strong side
effects observed in clinical trials of oltipraz in cancer chemopre-
vention [42] is caused by the unexpected pro-oxidative effect of
oltipraz,clearlythe ability of oltipraz to treat cardiovascular diseases
Figure 3. Effect of dh404 on Keap1-mediated Nrf2 ubiquitina-
tion and degradation. A, HEK 293 cells that were transfected with
plasmids of HA-Nrf2 (1000 ng), CBD-Keap1 (100 ng) and HA-Ub
(1000 ng) for 24 hours were treated with or without dh404 (200 nM)
in DMEM with 10% FBS for 2 hours as indicated. Ubiquitination of Nrf2
was determined by immunoprecipitation (IP) and immunoblot (IB)
analysis using appropriate antibodies as indicated. Inputs of 10 mgo f
whole cell lysates were utilized to monitor the protein expression levels
of target genes. B & C, HEK 293 cells that were transfected with plasmids
of HA-Nrf2 (800 ng) and CBD-Keap1 (80 ng) for 24 hours were treated
with or without dh404 (200 nM) and/or CHX (10 mg/ml) in DMEM with
10% FBS as indicated. D, HEK293 Cells were transfected with HA-Nrf2,
CBD-Keap1 or mutant Keap1 as described above, and then stimulated
with or without dh404 (200 nM) for 2 hours. Whole cell lysates were
subjected to immunoblot analysis using anti(a)Nrf2, aKeap1 or
aGapdah, as indicated. Results are representative of three independent
experiments.
doi:10.1371/journal.pone.0008391.g003
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Nrf2-driven signaling against oxidative stress and inflammatory
responses [43] is in late-stage clinical trails for the treatment of
chronic kidney diseases. Thus, further characterization of dh404-
mediated activation of Nrf2 signaling in the heart will thus facilitate
the development of novel therapeutic strategies for the treatment of
cardiac diseases.
In summary (Figure 9), we propose that, under normal
conditions, a single Keap1 protein is able to target multiple Nrf2
proteins for destruction via the ubiquitin-proteasome system.
However, when the ability of Keap1 to efficiently target Nrf2
proteins for degradation is disturbed, the capacity of Keap1
binding to Nrf2 is dramatically reduced [27]. Dh404 reacts with
Cys-151 of Keap1 to inhibit the Keap1-dependent Nrf2
degradation. Thus, newly synthesized Nrf2 proteins will saturate
the binding capacity of Keap1, and results in additional free Nrf2
proteins that accumulate in the cytoplasm, thereby triggering Nrf2
nuclear translocation and subsequent transcription, such as
expression of antioxidant genes to suppress oxidative stress. Our
results also demonstrate that dh404 suppresses oxidative stress via
the activating of Nrf2 signaling in cardiomyocytes, as well as
support the notion that dh404 as a novel Nrf2 activator possesses
potential for the treatment of heart disease.
Materials and Methods
Animals and Treatment
Ethics statement. All procedures involving rat and mice
were conducted in accordance with National Institutes of Health
regulations and guidelines for the use and care of experimental
Figure 4. Effect of dh404 on the Keap1/Cul3/Rbx1 complex-mediated Nrf2 degradation and on the assembling of Keap1/Cul3/Rex1
complex. HEK293 cells were transfected with plasmids of HA-Nrf2 (1000 ng), CBD-Keap1 (100 ng), HA-Cul3 (500 ng) or Myc-Rbx1 (400 ng) for
24 hours as indicated, and then were treated with or without dh404 (200 nM) in DMEM with 10% FBS for 2 hours as indicated.A, Recapitulation of
Keap1/Cul3/Rbx1 complex-mediated Nrf2 degradation in HEK293 cells. B, Effect of dh404 on Keap1/Cul3/Rbx1 complex-mediated Nrf2 degradation in
HEK293 cells. C, Effect of dh404 on assembling of Keap1/Cul3/Rbx1 complex in HEK293 cells. Cell lysates were subjected to immunoprecipitation (IP)
and IB analysis using antibodies of Nrf2, Keap1, HA, Myc, and Gapdh as indicated. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0008391.g004
Figure5. Regulation of interactionof Nrf2 with Keap1by dh404.
HEK293cellswere transfectedwith HA-Nrf2 andCBD-Keap1 as described
in Figure 3B, and treated with dh404 (200 nM) in DMEM with 10% FBS as
indicated. Immunoprecipitation (IP) and immunoblot (IB) analysis were
performed using appropriate antibodies as indicated. Results are
representative of three separated experiments. Cyo, cytosolic proteins;
Nucle, nuclear proteins.
doi:10.1371/journal.pone.0008391.g005
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South Carolina Institutional Animal Use and Care Committee.
Male ICR mice were purchased from Jackson laboratory and
housed under standard conditions in the Institution’s AAALAC
approved animal facility. Mice at 8 weeks of age were treated with
a single gavage administration of vehicle or dh404 (50 mg/kg).
Hearts were subsequently harvested at different time. Left
ventricular section sections and RNAs were prepared for
immunochemical staining and quantitative real time polymerase
chain reaction (Q-PCR) analysis as previously described [24].
Materials
A novel synthetic triterpenoid, dihydro-CDDO-trifluoroethyl
amide (dh404) of 2-cyano-3,12-dioxooleana-1-ene-28-trifluor-
oethylamide, was synthesized, purified, and analytically charac-
terized using similar methods as previously described [44]. The
chemical structure is illustrated in Figure 1. Plasmids expressing
wild-type Keap1, the chitin binding domain of the Bacillus circulans
chitinase A1 gene (CBD)- tagged wild-type Keap1 (CBD-Keap1),
Keap1 mutants of cysteine-to-serine mutations (C151S, C273S,
and C288S), wild-type Nrf2, hemagglutinin (HA)-tagged wild-type
Nrf2 (HA-Nrf2), HA-tagged ubiquitin (HA-Ub), HA-Cul3, Myc-
Rbx1, or ARE firefly luciferase reporter (pARE-Luc) were
prepared as previously described [26,27]. The Renilla luciferase
expression plasmid, pRL-TK, was purchased from Promega.
Adenovirus of murine Nrf2 and rat Nrf2 shRNA were purchased
from Wegen Inc. Protein G-Sepharose 4B, dimethyl sulfoxide
(Me2SO), cycloheximide (CHX), MG132, and angiotensin II (Ang
II) were purchased from Sigma-Aldrich. Probes of 29,79-dichloro-
fluorescin diacetate (DCFH-DA), dihydroethidium (DHE) and
dihydrorhodamine-123 (DHR-123) were purchased from Molec-
ular Probe (Eugene, OR).
Cell Culture, Adenoviral Infection, Transfection and
Reporter Gene Assay
NIH 3T3, HEK293, and H9C2 cells purchased from the
American Type Culture Collection were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). Rat neonatal cardiac myocytes were isolated
and cultured in high glucose DMEM supplemented with 8% horse
serum, 5% new-born calf serum as previously described [24]. H9C2
cells at ,80% confluent status were infected with 20 MOI of
adenovirus of beta-galactosidase (Ad-bGal), Nrf2 (Ad-Nrf2), control
scramble shRNA (Ad-scramble) and rat Nrf2 shRNA (Ad-Nrf2
shRNA) for 48 hours in serum-free DMEM. Transfections were
performed with Lipofectamone 2000 (Invitrogen) according to the
manufacture’s instruction. Each transfection was performed in
triplicateat leastthree times.Reporterassay was determined using a
dual luciferase assay kit (Promega) as previously described [45].
Immunofluorescence Assays
NIH 3T3 cells were grown on glass coverslips, transfected with
the HA-Nrf2 and the CBD-Keap1 expression plasmids with a
ratio of 10:1 and then fixed with 4% paraformaldehyde at 4uC
overnight. Immunofluorescence staining was performed with
rabbit anti-CBD antibodies (S6654S, New England Biolabs Inc.)
and mouse anti-HA antibodies (F-7, sc-7392, Santa Cruz
Biotechnology Inc.). H9C2 cells infected with Ad-Nrf2 or Ad-
Nrf2 shRNA and rat neonatal cardiomyocytes treated with vehicle
or dh404 (0.2 mM) for 1 hours were fixed as mentioned above, and
Figure 6. Dh404-induced activation of Nrf2 in H9C2 cardiomyocyte. Sub-confluent cells were transfected with ARE-luc (200 ng) and pRL-TK
(10 ng) for 24 hours, and then cultured with serum-free DMEM for another 24 hours. The quiescent cells were stimulated with dh404 as indicated,
and then subjected to ARE reporter assays (A) as well as immunoblot analysis of cytosolic and nuclear Nrf2 expression (B, left panel) or
immunochemical staining of Nrf2 (B, right panel).
doi:10.1371/journal.pone.0008391.g006
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Biotechnology Inc.). F-actin was stained by Alexa FluorH 488
phalloidin (Invitrogen). Cardiac myosin heavy chain was stained
using mouse monoclonal anti-cardiac myosin heavy chain (ab15,
Abcam Inc.). A standard protocol of immunochemical staining
was described in Supplemental Methods S1. Confocal microscopic
analysis was performed as previously described [24].
Immunoprecipitation and Immunoblot Analysis
Cell lysates were subjected to immunoprecipitation and
immunoblot analysis as previously described [46]. Nuclear and
cytoplasmic subcellular fractions were obtained using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce) following
the manufacturer’s instructions. Primary antibodies of Nrf2
(H-300, sc-13032), HA (F-7 sc-7392), Keap1 (E-20 sc-15246),
Figure 7. Dh404-induced inhibition of O2
.2 and ONOO
2 formation in H9C2 cardiomyocytes. A, Cells infected with 20 MOI of Ad-bGal, Ad-
Nrf2, Ad-scramble or Ad-Nrf2 shRNA for 48 hours were stimulated with angiotensin II (Ang II, 0.5 mM) for 1 hour. B, Cells infected with 20 MOI of Ad-
scramble or Ad-Nrf2 shRNA in the absence or presence of dh404 (200 nM) for 48 hours were stimulated with Ang II (0.5 mM) for 1 hour. C, Cells
infected with 20 MOI of Ad-bGal, Ad-Nrf2, Ad-scramble or Ad-Nrf2 shRNA for 48 hours were stimulated with Ang II (2 mM) for 1 hour. D, Cells infected
with 20 MOI of Ad-scramble or Ad-Nrf2 shRNA in the absence or presence of dh404 (200 nM) for 48 hours were stimulated with Ang II (2 mM) for
1 hour. O2
.2 and ONOO
2 formation was quantified as described in ‘‘Materials and Methods’’. *p,0.05 vs control (2); #p,0.05 vs Ad-scramble Ang II
(n=8).
doi:10.1371/journal.pone.0008391.g007
Dh404, a Novel Nrf2 Activator
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8391GAPDH (FL-335, sc-25778), ubiquitin (P4D1, sc-8017) and
Histone H3 (FL-136, sc-10809) were purchased from Santa Cruz
Biotechnology. An antibody of Myc (9b11, 2276) was purchased
from Cell Signaling Technology. An antibody of CBD (S6654S)
was purchased from New England Biolabs Inc.
Measurement of Intracellular ROS and RNS
Generation of ROS and RNS was assessed by the measurement
of superoxide (O2N
2), hydrogen peroxide (H2O2), and peroxyni-
trite (ONOO
2) generation using the fluorescent probes DHE [47],
DCFH-DA [48] and DHR-123 [49], respectively. DHE, a
nonfluorescent membrane-permeant probe, interacts with O2N
2,
leading to the liberation of membrane-impermeant ethidium
cations that fluoresce on intercalating with nuclear DNA.
DCFH-DA diffuses through the cell membrane and is hydrolyzed
by intracellular esterases to nonfluorescent dichlorofluorescin
(DCFH) that is rapidly oxidized to highly fluorescent dichloro-
fluorescein by ROS such as hydrogen peroxide (H2O2), hydroxyl
radical (?OH), and hydroperoxides (ROOH). DHR-123 is
oxidized by ONOO
2 to the highly fluorescent product rhodamine
in vitro. For each experiment, 8 fields were randomly chosen to
photograph, and integrated optical density (IOD)/per cell of the
images was quantified with Image Pro Plus software. Triplicate
experiments were repeated four times.
Statistical Analysis
Values are expressed as mean 6 S.E.M. The data were
analyzed using analysis of variance with the Newman-Keuls’ test
unless specified. Values of p,0.05 were considered to be
statistically significant.
Figure 8. Dh404-mediated Nrf2 activation in rat neonatal cardiomyocytes and murine hearts. A, Upper panel; left ventricular sections
from mice (n=3) treated with vehicle or dh404 (50 mg/kg) for 6 hours. Nrf2 expression and nuclear translocation were analyzed using confocal
microscopy. Red is Nrf2; Green is cardiac myosin heavy chain; Blue is nuclei. Lower panel; semi-quantification of Nrf2 expression was performed by
measuring integrated optical density (IOD)s of red signal of Nrf2 staining in 4 randomly chosen fields in each tissue section. Two sections from each
mouse treated with or without dh404 were randomly chosen for analysis. B, Q-PCR analysis of dh404-induced expression of Nrf2 target genes in the
heart. *p,0.05 vs vehicle, n=3.
doi:10.1371/journal.pone.0008391.g008
Figure 9. A model of dh404-induced activation of Nrf2. Under
normal conditions, a single Keap1 protein is able to target multiple Nrf2
proteins for destruction via ubiquitin-proteasome system, and only a
small portion of Nrf2 proteins is translocated into the nuclus to activate
Nrf2-driven transcription. Dh404 interacts with Cys-151 of Keap1 to
inhibit the Keap1-dependent degradation of Nrf2. Thus, newly
synthesized Nrf2 proteins saturate the capacity of Keap1 binding with
Nrf2, accumulate in the cytoplasm and subsequently translocate into
the nucleus, thereby facilitating Nrf2-driven transcription of antioxidant
genes to protect against oxidative stress.
doi:10.1371/journal.pone.0008391.g009
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Methods S1
Found at: doi:10.1371/journal.pone.0008391.s001 (0.03 MB
DOC)
Figure S1 Efficacy of adenoviral over-expression of Nrf2 and
Nrf2 shRNA in H9C2 cardiomyocytes. A, Cells infected with
different MOI of adenovirus of beta-galactosidase (Ad-bGal) and
Ad-Nrf2 for 48 hours, and then subjected to Western blot analysis
(Left panel) and immunochemical staining of Nrf2 (Right panel, 20
MOI for Ad-bGal or Ad-Nrf2). Western blot analysis demonstrat-
ed that Ad-bGal did not affect Nrf2 protein expression (data not
shown). Red is Nrf2; Green is F-actin; Blue is nuclei. B, Cells
infected with different MOI of Ad-scramble or Ad-Nrf2 shRNA
48 hours, and subjected to Q-PCR analysis of Nrf2 mRNA levels
(Left panel) and Nrf2 protein levels (Right panel, 20 MOI of Ad-
scramble or Ad-Nrf2) *p,0.05 vs control (0), (n=4). Q-PCR
analysis demonstrated that Ad-bGal did not affect Nrf2 mRNA
expression (data not shown). Red is Nrf2; Green is F-actin; Blue is
nuclei.
Found at: doi:10.1371/journal.pone.0008391.s002 (1.51 MB TIF)
Figure S2 Dh404 up-regulates Nrf2 in rat neonatal cardiomy-
ocytes. Rat neonatal cardiomyocytes were treated with or without
dh404 (0.2 mM) for 1 hours, and then subjected to immunochem-
ical staining as described in ‘‘Material and Methods’’. Results are
representative of three separated experiments. Red is Nrf2; Green
is cardiac myosin heavy chain; Blue is nuclei.
Found at: doi:10.1371/journal.pone.0008391.s003 (1.47 MB TIF)
Figure S3 Dh404-induced inhibition of O2.- and ONOO-
formation in H9C2 cardiomyocytes. A, B, Cells were pretreated
with oltipraz (20 mM) for 48 hours, and then were stimulated with
Ang II at doses of 0.5 mM (O2.- measurement) or 2 mM (ONOO-
measurement) for 1 hour. O2.- and ONOO- formation was
quantified as described in ‘‘Material and Methods’’. *p,0.05 vs
control (-); #p,0.05 vs Ang II (+), (n=8). ns, non-significant.
Found at: doi:10.1371/journal.pone.0008391.s004 (0.31 MB TIF)
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